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Turning T cells on: epigenetically enhanced
expression of effector T-cell costimulatory
molecules on irradiated human tumor cells
Anita Kumari, Ercan Cacan, Susanna F Greer and Charlie Garnett-Benson*
Abstract
Background: Sub-lethal doses of radiation can alter the phenotype of target tissue by modulating gene expression
and making tumor cells more susceptible to T-cell-mediated immune attack. We have previously shown that sub-
lethal tumor cell irradiation enhances killing of colorectal carcinoma cells by tumor-specific cytotoxic T cells by
unknown mechanisms. Recent data from our lab indicates that irradiation of tumor cells results in the upregulation
of OX40L and 41BBL, and that T cells incubated with irradiated tumor cells displayed improved CTL survival,
activation and effector activity. The objective of this current study was to determine the mechanism of enhanced
OX40L and 41BBL expression in human colorectal tumor cells.
Methods: Two colorectal carcinoma cell lines, HCT116 and SW620, were examined for changes in the expression of
41BBL and OX40L in response to inhibition of histone deacetylases (using TSA) and DNA methyltransferases (using
5-Aza-2′-deoxycytidine) to evaluate if epigenetic mechanisms of gene expression can modulate these genes. Tumor
cells were treated with radiation, TSA, or 5-Aza-dC, and subsequently evaluated for changes in gene expression
using RT-qPCR and flow cytometry. Moreover, we assessed levels of histone acetylation at the 41BBL promoter
using chromatin immunoprecipitation assays in irradiated HCT116 cells.
Results: Our data indicate that expression of 41BBL and OX40L can indeed be epigenetically regulated, as
inhibition of histone deacetylases and of DNA methyltransferases results in increased OX40L and 41BBL mRNA and
protein expression. Treatment of tumor cells with TSA enhanced the expression of these genes more than
treatment with 5-Aza-dC, and co-incubation of T cells with TSA-treated tumor cells enhanced T-cell survival and
activation, similar to radiation. Furthermore, chromatin immunoprecipitation experiments revealed significantly
increased histone H3 acetylation of 41BBL promoters specifically following irradiation.
Conclusions: Full understanding of specific mechanisms of immunogenic modulation (altered expression of
immune relevant genes) of irradiated tumor cells will be required to determine how to best utilize radiation as a
tool to enhance cancer immunotherapy approaches. Overall, our results suggest that radiation can be used to make
human tumors more immunogenic through epigenetic modulation of genes stimulatory to effector T-cells.
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Background
Previous reports by us and others demonstrate that sub-
lethal doses of radiation alter the expression of genes
within tumor cells [1-3]. Furthermore, it has been dir-
ectly demonstrated that tumor irradiation, as well as
treatment with some chemotherapy drugs, results in in-
creased susceptibility to killing of tumor cells by cyto-
toxic T cells (CTLs) [1,4,5]. Notably, many genes that
are important for T-cell anti-tumor effector activity are
up-regulated following treatment with sub-lethal doses
of radiation [2,4,6]. However, the mechanisms of
radiation-mediated changes in the expression of such
immune stimulatory genes are poorly understood.
It is clear that human cells respond to DNA-damage
from ionizing radiation (IR) by inducing the expression
of a number of genes at the transcriptional level [4,7,8].
Induction of altered gene expression can be due to direct
cellular radiation effects or to radiation-induced changes
in cellular milieu. Direct cellular effects appear to be
regulated through parallel signaling pathways that ori-
ginate from the nucleus following DNA damage, as well
as signaling pathways that originate in the cytoplasm via
reactive oxygen species production [7,9]. These pathways
induce NF-kB activation and nuclear translocation
[10,11]. As would be expected, DNA damage by IR can
induce cellular stress responses, which result in activa-
tion of DNA damage repair pathways and apoptotic
pathways [6,12]. Interestingly, regulation of the expres-
sion of a variety of genes, not related to known or typical
DNA repair or apoptotic pathways, also occurs [2,13,14].
Indeed, we previously examined 23 human carcinoma
cell lines for their phenotypic response to sub-lethal
doses of IR [4], and found that RT increased the expres-
sion of several genes commonly down-regulated by tu-
mors to escape immune recognition and elimination
[15-20], including Fas (CD95), Intercellular adhesion
molecule-1 (ICAM-1/CD54), tumor associated antigens
(TAA) and major histocompatibility (MHC)-Class I.
Most recently we found that radiation enhances the ex-
pression of OX40 ligand (OX40L/TNFSF4/CD134L/
CD252) and 41BB ligand (41BBL/TNFSF9/CD137L), im-
portant co-stimulators of effector CTLs on tumor cells
(submitted manuscript).
To elicit an effective immune response against tumors,
T cells need to recognize tumor antigens presented by
MHC in conjunction with appropriate co-stimulation
[21,22]. In the absence of proper co-stimulation, these
anti-tumor T cells become anergic. Proteins such as
41BBL and OX40L represent important co-stimulators
of effector CTL activity [23-26], and we have seen sub-
lethal doses of radiation increase their expression in
human tumor cells; however, the mechanisms regulating
radiation-enhanced modulation of the expression of
these two genes remain unclear. OX40 (TNFRSF4/
CD134) was originally characterized as a transiently
expressed co-stimulatory molecule regulating CD4 and
CD8 immunity [27], and signaling through OX40
promotes T-cell survival and expansion [28]. 41BBL co-
stimulation of 41BB (TNFRSF9/CD137) on tumor-
specific T cells is important for T-cell proliferation
[29,30], cytokine production, and activation [31]. En-
gagement of OX40 and 41BB by agonist antibodies
increases immunity against tumors, resulting in long-
term survival [32] in a number of murine tumor models
[33,34]. Recent evidence indicates that expression of
41BBL is transcriptionally activated by HDAC inhibitors
in leukemia cell lines [35], and that HDAC11 plays an
essential role in regulating OX40L expression [36]. Inter-
estingly, radiation has been shown to inhibit the expres-
sion of HDAC1 and HDAC2 [37], and we have seen
enhanced cytolysis by T-cells following tumor irradi-
ation. Thus, epigenetic mechanisms may be at work dur-
ing radiation-enhanced susceptibility to T-cell killing.
Epigenetic changes such as histone modifications and
DNA methylation play important roles in regulating
gene expression. DNA methyltransferase enzyme (DNM
T1) adds methyl group to cytosine residues [38]. DNA
hypermethylation of CpG dinucleotides accumulates in
promoter regions of genes and contributes to their loss
through epigenetic silencing. Promoter hypermethylation
and genome-wide hypomethylation alters genes expres-
sion in colorectal cancer [39]. It has been found that
genes having hypermethylation also exhibit altered
acetylation and methylation of histones [40]. Histone
acetylation via histone acetyltransferases (HATs) is an-
other major epigenetic mechanism controlling gene ex-
pression [41-43]. Gains in histone acetylation neutralize
the positive charge on lysine residues and contribute to
disrupted nucleosome structure, allowing unfolding of
DNA, increased transcription factor access and en-
hanced gene expression [44-46]. HDACs remove acetyl
groups from histones and return DNA to a less access-
ible conformation, thereby decreasing transcription
[47-49]. Alterations in HAT and HDAC activity have
been identified in many human cancers [50,51]. HDAC
inhibitors (HDACi) therefore promote hyperacetylation
of histones, which in turn leads to chromatin relaxation
and selective expression of genes.
The roles of DNA methylation and histone acetylation
in the expression of OX40L and 41BBL in response to
radiation have not been investigated. Hence, we designed
the present study to test the hypothesis that irradiation
leads to increased expression of OX40L and 41BBL in
colorectal tumor cells via epigenetic regulation. We
measured the expression of effector CTL co-stimulatory
molecules OX40L and 41BBL on human colorectal
tumor cells lines after treatment with trichostatin (TSA)
and 5-Aza-2′-deoxycytidine (5-Aza-dC). Ours is the first
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study to report that a) OX40L and 41BBL expression in-
creases in CRC cells when DNMTs are inhibited, b) ex-
pression of OX40L and 41BBL increases in human CRC
cells when HDACs are inhibited, c) HDAC inhibition in
CRC cells can increase the activation and survival of T
cells, and d) radiation treatment of tumor cells results in
epigenetic modification of the histones in the promoter
of the costimulatory gene 41BBL. The use of ionizing ra-
diation to specifically enhance cancer immunotherapy
(CIT) strategies through epigenetic modulation of genes
stimulatory to CTLs will have a broad impact on cancer
therapy approaches and will extend the use of radiation
into new directions.
Methods
Cell lines
Human colorectal carcinoma cell lines HCT116 cells
were obtained from the laboratory of tumor immun-
ology and biology, NCI, NIH. The cell line SW620 was
kindly provided by Zhi-Ren Liu [52] from Georgia State
University, Department of Biology. All cells were cul-
tured as recommended by ATCC and tested periodically
to ensure absence of Mycoplasma. Cells were incubated
at 37°C incubator with 5% CO2.
Reagents
5-Aza-2′-deoxycytidine (5-Aza-dC) and Trichostatin A
(TSA) were purchased from Sigma-Aldrich (St. Louis,
MO). Antibodies recognizing histone H3 and acetylated
histone H3 were from Millipore (Lake Placid, NY). Cell
viability following treatment was determined using Try-
pan blue dye exclusion on a Countess automated cell
counter (Life Technologies).
Irradiation
A RS-2000 biological X-ray irradiator (Rad source tech-
nology, Suwanee, GA) was used to irradiate tumor cells.
Cells were irradiated at a dose rate of 2Gy/min by set-
ting irradiator voltage and current at 160 kV and 25 mA,
respectively. Cells were maintained in suspension and
kept on ice during irradiation. Immediately after irradi-
ation, the culture media was replaced with the fresh
media.
Quantitative real time PCR
Cells were plated and treated with 5AZA-dC (20 uM),
TSA or 10Gy radiation. Untreated control cells were cul-
tured with the equivalent amount of DMSO present in
drug treated samples. Adherent and viable cells were
collected and RNA was extracted from tumor cells using
RNeasy mini kit (Qiagen Inc. Valencia, CA) according to
manufacturer’s instructions. Purified RNA was DNase-
treated by Rnase-free DNase (Qiagen Inc. Valencia, CA)
following manufacturer’s instructions. Expression of
OX40L and 41BBL mRNA was determined using real time
RT-PCR. cDNA was synthesized using 500 ng of mRNA.
Amplification of cDNA was done using Dynamo cDNA
synthesis kit (Finnzymes. Vantaa, Finland). Quantitative
RT-PCR was conducted using TaqMan gene expression
assay (Applied Biosystems; OX40L; Hs00967195, 41BBL;
Hs00169409, and HPRT; Hs99999909) according to man-
ufacturer’s protocol. PCR thermal cycling condition was
50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15
sec and 60°C for 1 min in a total volume of 20 μl/reaction.
Data were collected using a 7500 Real Time PCR System.
All samples were run in duplicate. Hypoxanthine
phosphoribosyltransferase (HPRT) was used as an en-
dogenous house-keeping control gene and samples were
normalized to expression of this gene, which was un-
changed by treatment. Data were analyzed using the com-
parative Ct method [53].
Flow cytometry
Cells were stained with primary labeled mAb CD137L
(41BBL)-PE, and CD252 (OX40L)-PE purchased from
BioLegend (San Diego, CA). Surface staining was done
in cell staining buffer for 30 min on ice. Flow cytometry
data were acquired on BD Fortessa and analyzed with
FlowJo software (TreeStar, version 9.6). Isotype control
was kept less than 5% in all the samples. Expression was
considered increased if the absolute percent positive
population increased by 10% or greater.
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assays were performed as previously described [54].
Briefly, 48 h after irradiation (10Gy) and TSA (500 nM)
treatment cells were seeded at a density of 2.0 × 106 and
crosslinked with 1% formaldehyde. The crosslinking reac-
tion was stopped by the addition of 0.125 M glycine. Cell
nuclei were isolated and concentrated by lysing in SDS
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.0,
plus protease inhibitors) on ice followed by flash freezing
in liquid nitrogen. Cell nuclei were sonicated using a
Bioruptor to generate an average of 500 bp of sheared
DNA; DNA shearing was confirmed by subjecting lysates
to agarose gel electrophoresis. Sonicated lysates were then
precleared with salmon-sperm/agarose beads (Upstate)
and 5% of the total lysate was stored as input for
normalization. Half of the remaining lysate was immuno-
precipitated with control antibody, and the other half was
immunoprecipitated with 5 μg of indicated antibody
overnight at 4°C. Following an additional two hour immu-
noprecipitation with salmon-sperm/agarose beads, all
samples were washed with each of the following buffers:
low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris pH 8.0, 150 mM NaCl), high salt buffer (0.1%
SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris pH 8.0,
500 mM NaCl), LiCl buffer (0.25 M LiCl, 1% NP40, 1%
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DOC, 1 mM EDTA, 10 mM Tris pH 8.0), and 1xTE buf-
fer. DNA was eluted with SDS elution buffer (1% SDS, 0.1
M NaHCO3) and then cross-links were reversed overnight
with 5 M NaCl at 65°C and immunoprecipitated DNA
was isolated using phenol:chloroform:isopropanol mix
(Invitrogen) as per the manufacturer’s instructions. Iso-
lated DNA was quantified by real time PCR on an ABI
prism 7900 (Applied Biosystems, Foster City, CA) using
the following primers and probe for 4-1BBL: forward, 5’-
GCA CGC ATA GAC ATA AAT TGG C-3’, reverse, 5’-
TCT GTG TCT CCC CGT TAA C -3’ and probe, 5’-TCC
ACC CAC TGC AGA GGC AAT CAA-3’; for GAPDH:
forward, 5’-AAT GAATGG GCA GCC GTTA-3’, reverse,
5’-TAG CCT CGC TCC ACC TGA CT-3’ and probe, 5’-
CCT GCC GGT GAC TAA CCC TGC GCT CCT-3’; and
for CIITA: forward, 5’-CAG TTG GGA TGC CAC TTC
TGA-3’, reverse, 5’- TGG AGC AAC CAA GCA CCT
ACT-3’ and probe, 5’-AAG CAC GTG GTG GC-3’.
Values generated from real time PCR reactions were cal-
culated based on standard curves generated, were run in
triplicate reactions and were analyzed using the SDS 2.0
program.
Generation TAA-specific cytotoxic T-lymphocytes
PBMCs from HLA-A2+ donors were purchased from
Hemacare (Van Nuys, CA) for the generation of antigen
specific CTLs as described elsewhere [4,55,56]. These
leukapheresis samples, derived from HLA-A2+ patients,
were obtained from Hemacare with appropriate in-
formed consent. The use of these de-identified and
commercially purchased tissues is under a human investi-
gation protocol approved by the GSU IRB (exempt ap-
proval #H13305). Briefly, PMBCs were allowed to adhere
to T150 flask for 2 hr in AIM-V media. After 2 hr, non-
adherent cells were removed for lymphocyte isolation. Ad-
herent cells were cultured for seven days in the presence
of 100 ng/ml of human granulocyte colony stimulating
factor (GM-CSF) and 20 ng/ml of IL-4 (Miltenyi Biotec,
Inc. Auburn, CA) in AIM-V media and 500 ng/ml CD40L
(Millipore corporation, Temecula, CA) was added on day
five to mature the DCs. On day seven DCs were collected
and pulsed with 40 μg/mL of HLA-A2 binding CEA pep-
tide (YLSGANLNL (CAP-1; [56],) peptide for 4 hr in a
37°C 5% CO2 incubator. Unused DCs were frozen and
stored in liquid nitrogen for subsequent restimulations.
DCs loaded with peptide were subsequently irradiated
with 50Gy. Immunomagnetic beads (Miltenyi Biotec Inc.
Auburn, CA) were used to isolate CD8+ T cells from the
non-adherent cells, following manufacturer instructions.
Subsequently, isolated CD8+ T cells were co-cultured with
peptide pulsed DCs. IL-7 (Millipore, Temecula, CA) at
10 ng/ml and IL2 (Millipore, Temecula, CA) at 30U/ml
were added to each well on the first and third day, respect-
ively. T-cells were restimulated in this manner weekly
using mature autologous DCs. Restimulated T cells were
isolated over ficoll on day seven of culture, and used in a
T-cell activation and survival assays.
T-cell activation and survival assay
1 × 103 colorectal tumor cells were irradiated or treated
with TSA and plated in 96-well plate for 48 hr. 1 × 104
human CEA specific CD8+ T cells were subsequently
added and co-cultured with the colorectal tumor cells
for 48 hr. The percent of CD8+ T cells expressing CD69
or CD25 was measured by flow-cytometry. In parallel
experiments, 7AAD was used to measure T-cell death.
Flow cytometry data were acquired on BD Fortessa and
analyzed with FlowJo software (TreeStar, version 9.6).
The live cells population was gated on the FSC and SSC
scatter plots for analysis of surface proteins. No live cells
gate was used for cell death analysis samples. T cell
stimulation for 24 h using a (1×) cocktail of PMA and
ionomycin (eBioscience) was used as a positive control
for activation of TAA-specific T-cells.
Statistical analysis
Statistical differences between groups were calculated
using un-paired two-tailed student T-test and calculated
at 95% confidence using Graphpad by Prism. P-values
less that 0.05 were considered statistically significant.
Results
OX40L and 41BBL transcripts increase when DNMTs and
HDACs are inhibited
Exposure of human carcinoma cell lines to sub-lethal ra-
diation results in enhanced susceptibility to lysis by
tumor specific cytotoxic T cells (CTLs) [4,5], and co-
stimulatory proteins such as 41BBL and OX40L repre-
sent important regulators of effector CTL activity
[22,26]. These ligands for OX40 (OX40L/CD134L) and
41BB (41BBL/CD137L) are normally expressed on anti-
gen presenting cells and activated endothelial cells.
However, we have recently demonstrated expression of
both proteins on tumor cells following treatment with
radiation (submitted manuscript). Others have reported
that changes in DNA methylation can upregulate the ex-
pression of costimulatory proteins in human tumor cells
[57,58]. The dynamics of the induction of DNA methyla-
tion in irradiated tissue is currently unknown, and the role
of methylation in expression of co-stimulatory molecules
in response to radiation has not been investigated. We
began our investigation by treating cells with 5-Aza-2′-
deoxycytidine (5-Aza-dC) to inhibit DNA methylation in
order to determine if this would alter expression of 41BBL
or OX40L in human CRC cells. 5-Aza-dC is a DNA
methyltransferase inhibitor (DNMTi) and is incorporated
into DNA resulting in the rapid loss of DNA methyl trans-
ferase activity [59]. The human colorectal cell line
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HCT116 was treated with 5-Aza-dC for 48 or 72 hr, and
OX40L and 41BBL mRNA was quantified. OX40L mRNA
increased 1.4-fold (Figure 1A) and 41BBL mRNA in-
creased approximately 2-fold (Figure 1B) at both 48 and
72 hr post-treatment with 5-Aza-dC. OX40L mRNA
increased over time in tumor cells treated with radiation,
as there was a 2.3-fold increase at 48 hr and a 3.6-fold in-
crease at 72 hr (Figure 1A). Radiation induced a similar
increase in 41BBL transcript levels. Interestingly, this tem-
poral increase was not observed in tumor cells treated
with 5-Aza-dC as relatively equal levels of both OX40L
and 41BBL mRNA were detected after 48 hr (gray bar)
and 72 hr (black bar) drug treatment. Moreover, the level
of OX40L mRNA in cells treated 5-Aza-dC never
exceeded those observed 72 h post-IR.
HDACs enzymes remove acetyl groups from histones
and suppress gene transcription. Recent studies have
shown that HDAC inhibitors also have immune-
modulatory properties, such as increasing expression of
HLA-DR, ICAM-1 and B7-2 in acute myeloid leukemia
cell lines [60]. We next asked if inhibition of HDACs
would result in increased expression of OX40L and
41BBL similar to the increase seen in radiation-treated
cells. For these experiments we used Trichostatin A
(TSA), an inhibitor of the class I and class II family of
HDAC enzymes, and evaluated OX40L and 41BBL
mRNA expression. HCT116 cells treated with TSA for
48 hr (gray bar) contained more OX40L (Figure 1A) and
41BBL mRNA (Figure 1B) as compared to cells treated
with 5-Aza-dC for 48 or 72 hr. Messenger RNA levels
Figure 1 5AZA and TSA up-regulate the expression of OX40L and 41BBL mRNA in HCT116 cells. (A) OX40L, and (B) 41BBL mRNA level
was quantified using qPCR as described in Methods. Cells were plated and treated with 5AZA-dC (20 uM), TSA (500 nM) or 10Gy radiation (IR).
Adherent cell were collected after 48 (gray bar) and 72 hr (black bar) and mRNA values were compared to the level of gene expression see in
untreated control samples (white bar), which was set to 1. Values represent mean ± SEM of technical replicates. Experiments were repeated at least
three times with similar results. (C) Cells were plated and untreated (DMSO) or treated with 5AZA-dC (20 uM), TSA (500 nM, 250 nM or 125 nM) or
10Gy radiation (IR). Both floating and adherent cells were collected after 48 h of treatment and tumor cell viability was determining using trypan
blue dye exclusion. Values represent mean ± SEM of three independent experiments. (D) OX40L and (E) 41BBL mRNA level was quantified.
Adherent cell were collected after 8 (gray bar) and 24 hr (black bar) and mRNA values were compared to the level of gene expression in
untreated control samples (white bar). Values represent mean ± SEM of technical replicates. Experiments were repeated at least three times with
similar results. (F) Cells were plated and untreated (DMSO) or treated with 5AZA-dC (20 uM), TSA (500 nM, 250 nM or 125 nM) or 10Gy radiation
(IR). Adherent cells were collected after 24, 48, and 72 h of treatment and live tumor cell number was determining using trypan blue dye
exclusion. Values represent mean ± SEM of three independent experiments. Significant P-value shown in the indicated groups was determined at
48 h. *indicates P value of <0.05, **indicates P value of <0.001.
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decreased after 72 hr (gray bar) of TSA treatment; we
note that these cells were sensitive to TSA toxicity and
began dying after 48 hr TSA treatment though this loss
of viability did not reach significance (Figure 1C). It is
likely that mRNA expression at 48 and 72 h is not repre-
sentative of early radiation events. As changes in pro-
moter activation are often an early event we next
evaluated cells at 8 and 24 h post-treatment. We found
no significant increase in OX40L mRNA. Surprisingly,
while radiation did not induce a significant increase in
41BBL RNA at 8 or 24 h, TSA did at both time points
(Figure 1). Indeed the increase in 41BBL mRNA at 24 h
(4-fold) exceeded levels observed after 48 h treatment
(Figure 1B). 5-Aza-dC began to increase 41BBL as early
as 24 h after treatment by slightly greater that 2-fold
(Figure 1E) and this increase was maintained during 48
and 72 h treatment (Figure 1B). However, both radiation
and TSA induced more 41BBL mRNA than 5-Aza-dC at
their respective times of maximum induction. Overall,
inhibition of both HDACs and DNMTs increased the
levels of OX40L and 41BBL mRNA in HCT116 cells.
To determine if epigenetic regulation of these genes
was a common mechanism observable in carcinoma
cells, we evaluated a second human CRC cell line,
SW620. Again, SW620 cells were treated with 5-Aza-dC
and TSA for 48 or 72 hr and mRNA expression was
measured by qRT-PCR. Overall, SW620 cells were more
responsive to these treatments than HCT116 cells. 5-
Aza-dC upregulated the expression of OX40L by 5.3 fold
(Figure 2A) and 41BBL by 3.5 fold (Figure 2B) in SW620
Figure 2 5AZA and TSA up-regulate the expression of OX40L and 41BBL mRNA in SW620 cells. (A) OX40L, and (B) 41BBL mRNA was
quantified in SW620 cells using qPCR. Cells were plated and treated with 5AZA-dC (20 uM), TSA (250 nM) or 10Gy radiation (IR). Adherent cell
were collected after 48 (gray bar) and 72 hr (black bar) and mRNA values were compared to the level of gene expression see in untreated control
samples (white bar), which was set to 1. Values represent mean ± SEM of technical replicates. Experiments were repeated at least three times with
similar results. (C) Cells were plated and untreated (DMSO) or treated with 5AZA-dC (20 uM), TSA (500 nM, 250 nM or 125 nM) or 10Gy radiation
(IR). Both floating and adherent cells were collected after 48 h of treatment and tumor cell viability was determining using trypan blue dye
exclusion. Values represent mean ± SEM of three independent experiments. (D) OX40L and (E) 41BBL mRNA level was quantified after 8 (gray
bar) and 24 hr (black bar) and compared to the level of gene expression in untreated control samples (white bar). Values represent mean ± SEM
of technical replicates. Experiments were repeated at least three times with similar results. (F) Cells were plated and left untreated (DMSO) or treated
with 5AZA-dC (20 uM), TSA (500 nM, 250 nM or 125 nM) or 10Gy radiation (IR). Adherent cells were collected after 24, 48, and 72 h of treatment
and live tumor cell number was determining using trypan blue dye exclusion. Values represent mean ± SEM of three independent experiments.
Significant P-value shown in the indicated groups was determined at 48 h. *indicates P value of <0.05, **indicates P value of <0.001.
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cells treated for 72 hr (gray bar). HDAC inhibition by
TSA robustly altered the expression of 41BBL mRNA
resulting in a 25-fold increase (Figure 2B), and again
resulted in a more modest upregulation of OX40L by
1.8-fold in SW620 cells treated for 72 hr (Figure 2A).
Interestingly, these cells were more sensitive to TSA tox-
icity (Figure 2C) and displayed significantly reduced cell
numbers following 48 and 72 h treatment with TSA
concentrations ranging from 500 nM to 125 nM
(Figure 2F). Viable cell numbers decreased with TSA
treatment time and dose (Figure 2C), however, RNA was
isolated and analyzed from the adherent and viable cells
remaining in the culture (Figure 2F) for our experiments
(Figure 2A & B). Moreover, we observed similar cell
numbers remaining between the treatment groups after
24 h treatment with TSA and next evaluated changes in
gene expression after 8 and 24 h treatment. Increased
message for OX40L could be detected as early as 24 h in
cells treated with radiation and 5-Aza-dC (Figure 2D)
and was further increased after 48 and 72 h (Figure 2A).
The largest increase in OX40L in response to TSA treat-
ment in SW620 cells was detected following treatment
for 8 h (2.7-fold) and was reduced slightly thereafter
(2.1-fold). We also evaluated 41BBL expression after 8
and 24 h treatment. No significant change in 41BBL
mRNA was observed at either of the earlier time points
in cells treated with 5-Aza-dC or radiation. In contrast,
a significant and robust increase in 41BBL expression
could be detected after both 8 and 24 hr TSA treatment
(20-fold) (Figure 2E) that was further increased after 72
hr treatment (Figure 2B). We noted that the relative
level of 41BBL mRNA in untreated control cells
appeared to be higher than OX40L mRNA levels in both
cell lines evaluated. Overall, the largest increases in
mRNA were detected for 41BBL mRNA following treat-
ment of CRC cells with TSA. We also found that TSA
induced robust mRNA changes at earlier times of treat-
ment (8 h and 24 h) while radiation-induced changes
took longer and were greatest at later times of treatment
(48 h and 72 h).
Following tumor cell irradiation only adherent and
proliferating cells were harvested for analysis. We have
previously demonstrated that irradiated tumor cells con-
tinue to proliferate and remain viable using this method
[6] (Figures 1C & 2C). HCT116 cells appear to be less
sensitive to TSA than SW620 cells as significantly re-
duced proliferation of treated HCT116 cells was
detected only when the highest dose of TSA (500 nM)
was used (Figure 1F). In contrast to TSA, there was very
little impact of 5-Aza-dC on viability of tumor cells 48 h
after treatment in either cell line (Figures 1C & 2C).
Though cell numbers were slightly reduced following 5-
Aza-dC treatment of SW620 cells this was not signifi-
cant (Figure 2F).
Surface expression of OX40L and 41BBL protein increases
when DNMTs and HDACs are inhibited.
The largest increase in mRNA was detected in
SW620 cells treated with 5-Aza-dC (OX40L, Fig-
ure 2A) or TSA (41BBL, Figure 2B), and we wanted
to determine if increased protein expression also oc-
curred. There was no significant difference in the
total cell number (Figure 2F) or the viability (data
not shown) of SW620 cells following 24 h hour
treatment with 125 nM TSA. As such,
we evaluated surface expression of 41BBL protein
by flow cytometry after 24 hr treatment with either
TSA (125 nM) or 5-Aza-dC. Untreated SW620 cells
expressed modest amounts of 41BBL on the surface
(38.4%), and as expected radiation increased the fre-
quency to 60.4% (Figure 3A). Treatment with 5-Aza
-dC had less of an impact on protein expression and
48% of cells expressed 41BBL after treatment with
the drug (Figure 3C). In contrast, TSA had a much
larger impact on protein expression and, similar to
radiation-induced expression, 61% of TSA-treated
SW620 cells expressed 41BBL (Figure 3D) (66% in
cells treated with 500 nM). Thus, relative changes in
41BBL protein expression (Figure 3A) and 41BBL
mRNA quantities (Figure 2B) were similar in this
cell line.
We next evaluated OX40L protein expression. SW620
tumor cells increased surface OX40L following exposure
to 10Gy of radiation (IR; 46.4%), as compared to un-
treated cells (DMSO; 23.1%) (Figure 3E). TSA increased
protein expression of OX40L to a similar magnitude
(46.7%) as irradiated cells. Again, as seen with 41BBL,
there was a smaller increase in surface OX40L detected
(31.1%) following treatment with 5-Aza-dC. This was
surprisingly low given the 3- to 5-fold increase in
OX40L mRNA seen in these cells upon 5-Aza-dC treat-
ment (Figures 2A & 2D). Thus, mRNA modulation of
the two genes (Figure 2) was similar to protein changes
by TSA and radiation (Figure 3), but not 5-Aza-dC. Fur-
thermore, the modulation of OX40L protein was less ro-
bust than that observed for 41BBL protein in SW620
cells (Figure 3B-3D & 3F-3H).
Overall, our results show that TSA-treated cells dem-
onstrated the largest increase in protein expression, and
the increase was at least as good as that observed follow-
ing treatment with radiation (Figure 3). As such, we fo-
cused our subsequent experiments on the impact of
TSA HDAC inhibition on co-stimulatory molecule ex-
pression. Our data reveal increased expression of OX40L
(53.2%) 48 hr after irradiation of HCT116 cells as com-
pared to untreated (0Gy) cells (30.7%) (Figure 4A-B &
4E). Expression of OX40L is detected on the surface of
56.6% TSA-treated HCT116 cells (Figure 4F) as com-
pared to expression in control (DMSO) cells (38.2%).
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Expression of 41BBL was also enhanced too much
greater levels following treatment with both IR (43.6%
10Gy) (Figure 4C-D & 4E) and TSA (58.6%-250 nM
TSA versus 23%-untreated) at 48 hr (Figure 4G). The
relative change in 41BBL surface expression compared
to untreated cells was larger that the change in OX40L
following TSA treatment in HCT116 cells (Figure 4H). Ele-
vated levels of these co-stimulatory proteins could still be
detected after 3- to 4-days of TSA treatment and radiation-
induced changes where greater after 72 h (data not shown).
Overall, both HCT116 and SW620 cells showed a more
robust increase in expression of 41BBL as compared to
OX40L protein expression upon TSA treatment.
Radiation increases histone H3 acetylation at the 41BBL
promoter
Our data indicates that 41BBL and OX40L are epigeneti-
cally regulated and radiation increases expression of
these genes in CRC cell lines. Histone acetylation facili-
tates transcription initiation by loosening interactions
between the histones and DNA. Whereas, HDACs re-
move these acetyl groups from histones which reduces
transcription. We observed that inhibition of HDACs by
TSA increased 41BBL mRNA expression and surface
protein levels in tumor cells. We observed that radiation
increased 41BBL gene expression in a similar manner
but was more robust at later times during treatment. As
Figure 3 TSA and ionizing radiation increase surface expression of co-stimulatory molecules in SW620 cells more than 5AZA. (A-D)
41BBL, and (E-H) OX40L protein expression on the surface of SW620 cells was evaluated by flow cytometry. Cells were either untreated (DMSO),
or treated with 5-Aza-dC (20 uM), TSA (125 nM) or 10Gy radiation (IR). Adherent cells were harvested 24 hr post treatment, and stained with
PE-labeled antibody to human OX40L or 41BBL. Isotype control stained cells were analyzed for each treatment group individually and set to 5%
positive. Isotype control staining is shown as the gray filled histogram and protein specific staining is shown as black line histogram for the FACS
plot data graphed in A and E. Experiments were repeated twice with similar results.
Kumari et al. Journal for ImmunoTherapy of Cancer 2013, 1:17 Page 8 of 16
http://www.immunotherapyofcancer.org/content/1/1/17
radiation has been reported to inhibit HDACs [37], we
next wanted to determine if radiation could be increas-
ing 41BBL expression by promoting increased promoter
histone acetylation. To explore whether histone modifi-
cations are regulated in part by radiation, we assessed
levels of histone acetylation at the 41BBL promoters
using chromatin immunoprecipitation (ChIP) assays in
both non-radiated and irradiated HCT116 cells. We
evaluated promoter acetylation at 48 h post-IR when
radiation-induced changes in mRNA levels were robust
(Figure 1). TSA-treated HCT116 cells were used as a
positive control for 41BBL promoter acetylation. As TSA
inhibits HDAC activity, we expect to see robust in-
creases in histone acetylation status following TSA
treatment. As expected, Figure 5A shows increased
acetylation at the 41BBL promoter following TSA treat-
ment (gray bar) as compared to untreated control cells
(white bar). Surprisingly, acetylated H3 histone levels
were significantly higher at 41BBL promoters in irradi-
ated cells (black bar). In contrast, similar levels of acety-
lated histone H3 were associated with the GAPDH
promoter in both untreated and irradiated HCT116 cells
(Figure 5B). Moreover, total levels of histone H3 were
similar at 41BBL and GAPDH promoters revealing that
there was no global change in overall histone levels
(data not shown). These data indicate that radiation
increases 41BBL expression by increasing histone
acetylation. To determine if radiation non-specifically
increases histone acetylation levels at other genes, his-
tone H3 ChIP assays were performed on the Class II
Figure 4 TSA and ionizing radiation treated HCT116 cells increase surface levels of 41BBL protein more than OX40L protein. (A, B and
F) OX40L, and (C, D and G) 41BBL protein expression on the surface of HCT116 cells was evaluated by flow cytometry. (E) Cells were untreated
(0Gy) or treated with 10Gy radiation (IR). (H) In separate experiments HCT116 cells were untreated (DMSO) or treated with either TSA (250 nM).
After 48 hr, cells were collected and stained with PE-labeled antibody to either OX40L and 41BBL. Control cell staining with a non-specific isotype
control antibody was less than 5% positive. Isotype control staining is shown as the gray filled histogram and protein specific staining is shown as
black line histogram for the FACS plot data graphed in E and H. Dotted line histogram in F and G indicates specific protein expression in
untreated cells. Values shown on histograms are for treated cells and untreated and treated values are displayed graphically in H for comparison.
Experiments were repeated three times with similar results.
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Transactivator (CIITA) promoter IV. Histone H3
acetylation levels were similar for non-irradiated,
irradiated and TSA treated cells at CIITA promoter IV
(Figure 5C), which suggests gene-specificity for
radiation-induced 41BBL promoter acetylation, likely
via HDAC inhibition.
Treatment of CRC cells with TSA enhances T-cell survival
and activation similar to co-incubation with irradiated
tumor cells
To investigate the impact of HDAC inhibition in tumor
cells on T-cell survival, we measured T-cell death by
7AAD staining after 48 hr co-incubation with tumor cells.
7AAD + staining determined cell death of 8.96% of CD8+
T cells incubated alone (Figure 6A). The frequency of dead
CD8+ T cells increased to 24.8% following co-incubation
with untreated SW620 cells (Figure 6B). Death of T-cells
following interaction with tumor cells has been reported
by others, and is thought to be caused by tumor expressed
PDL1, FasL and/or activation induced cell death (AICD)
[61-63]. Incubation of T-cells with SW620 cells, which
had been treated with TSA for 48 hr, reduced the
percentage of dead T cells to 17.6% (Figure 6D) similar to
incubation with irradiated tumor cells (16.6%). A reduc-
tion in T-cell death (18%) was also observed when T-cells
were co-incubated with TSA-treated HCT116 cells as
compared to untreated tumor cells (26%) (Figure 6E).
These data indicate that HDAC inhibition by TSA treat-
ment of tumor cells increases the survival of CD8+ T cells
following co-incubation with tumor cells.
CD25 and CD69 are surface markers expressed on
activated T cells [64]. Data from our lab supports the
hypothesis that changes in the expression of tumor-
expressed 41BBL and OX40L contribute to increased kill-
ing of irradiated tumor cells by CTLs (submitted manu-
script). We have also observed increased expression of
Figure 5 Histone acetylation at 41BBL promoters in non-radiated and irradiated cells. ChIP assays were carried out in non-irradiated,
irradiated (10 Gy), and TSA-treated (500 nM) HCT116 cells. Following 48 h of TSA treatment, lysates were immunoprecipitated with control
antibody or with anti-acetyl histone H3. Associated DNA was isolated and analyzed via real time PCR using primers spanning the 41BBL, GAPDH
and CIITA promoters. Real-time PCR values were normalized to the total amount of promoter DNA added (input). Input values represent 5% of
the total cell lysate. Values represent mean ± SEM of three independent experiments. **P < 0.005. A. Global levels of Histone H3 acetylation
associated with the 41BBL promoter. B. Global levels of Histone H3 acetylation associated with the GAPDH promoter. C. Global levels of
acetylated Histone H3 associated with the CIITA promoter.
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CD25 and CD69 on T cells following co-incubation with ir-
radiated tumor cells compared to non-irradiated tumor
cells. Lastly, we have observed increased viability of T cells
cultured with irradiated tumor cells. We next determined if
tumor cells treated with HDACi induced similar changes in
T cell activation. Non-treated, irradiated or TSA treated
tumor cells were co-cultured with CD8+ T cells, and after
48 hr the expression of CD25 on T cells was measured by
flow cytometry. We found that 29.5% of CD8+ T cells incu-
bated with untreated tumor cells expressed CD25
(Figure 7A), and this frequency was reduced compared to
activation of T cells incubated alone (34.1%) (Figure 7D).
This reduction is not surprising as reduced activity and ac-
tivation of T-cells following interaction with tumor cells
has been described by others [61-63]. The frequency of
CD25+ within the CD8+T cell population increased
following co-incubation with either radiation-treated (Fig-
ure 7B) or TSA-treated tumor cells to 35.3% (Figure 7C). In
fact, the frequency of activated T cells following co-
incubation with TSA-treated cells was equal to T cells not
co-incubated with tumor cells (34.1%). CD25 expression in
T-cells activated with PMA and ionomycin are shown as a
positive control (Figure 7E). We evaluated a second CRC
cell line and found that TSA-treated HCT116 cells also in-
creased the frequency of CD8+CD25+ cells to 41%, as com-
pared to the frequency activated in the presence of
untreated HCT116 cells (36.6%) (Figure 7F). Irradiated
tumor cells also increased CD25+ expression to 36.4% and
the dynamics of T-cell activated were similar in repeat ex-
periments. We observed a similar increase in the frequency
of CD69+ T cells following co-incubated with TSA-treated
or irradiated tumor cells (data not shown). These data sug-
gest that T cells exposed to TSA treated tumor cells have
improved activation. As a component of the IL-2 receptor,
CD25 it has been linked to increased survival in studies by
others and thus could be a contributor to the increased sur-
vival we observe following TSA treatment (Figure 6).
Discussion
Modulation of costimulatory molecules such as OX40L
and 41BBL appear to be particularly important for
maintaining effective immune responses against self-
antigens presented by tumor cells. Here, we report that
costimulatory molecule promoter histones can be acety-
lated in colorectal tumors in response to sub-lethal radi-
ation (Figure 5A). Most studies of radiation-induced
gene expression have used large cytotoxic doses of radi-
ation, and mechanisms of altered gene expression are
much less explored in cells receiving low or sub-lethal
doses of radiation. Results of this study suggest that radi-
ation therapy may be useful to specifically modulate
gene expression within tumor targets. This mechanism
Figure 6 Enhanced survival of T-cells co-incubated with CRC tumor cells treated with TSA. SW620 and HCT116 cells were treated with
DMSO, TSA (250 nM), or radiation (10Gy). After 48 hr, tumor cell were harvested and co-cultured with human CEA-specific CD8 + T-cells for
another 48 hr. Cell death was also measured in CD8+ T-cells cultured alone. Data were gated first gated on CD8+ population and the percent of
7AAD-positive within the CD8+ cell population is shown in (A-D) as zebra plots. (E) Representative graphs showing percentage of dead CD8+
T-cells. Experiments were repeated twice with similar results.
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would be useful against radioresistant cancer cells, and
could occur even in the absence of immunogenic cell
death (cell death that invokes enhanced antigen process-
ing and presentation) [65]. Full understanding of specific
mechanisms of immunogenic modulation (altered ex-
pression of immune relevant genes) [66] of irradiated
tumor cells will be required to determine how to best
utilize radiation as a “tool” to enhance cancer immuno-
therapy approaches.
Dramatic changes in DNA methylation are common
in cancer, and manifest primarily as global DNA
hypomethylation, paralleled by local hypermethylation at
gene promoters resulting in loss of gene expression
[67,68]. Tumor cells down-regulate the expression of
many genes needed for induction of effective anti-tumor
immune activity [15,16,18,19], and DNA methylation
may be one mechanism employed to accomplish this.
Our studies reveal that inhibition of DNMT in tumor
Figure 7 TSA-treated CRC tumor cells induce enhanced activation of CD8+ T-cells. SW620 cells were either (A) untreated, (B) irradiated or
incubated with (C) 250 uM TSA for 48 hr or as previously described. Tumor cells were subsequently co-cultured with human CEA-specific CD8 +
T-cells for 48 hr and the frequency of CD8 + CD25+ T-cells was measured by flow cytometry. T-cell activation was also measured in (D) CD8+
T-cells cultured alone or (E) activated with PMA and ionomycin (P/I) for 24 h. Data were gated first gated on CD8+ population and the percent
of CD25+ cells within the CD8+ cell population is shown in (A-E) as histogram plots. (F) a summary graph of results showing percentage of CD8
+ T-cells expressing CD25 in both SW620 and HCT116 cells. Experiments were repeated twice with similar results.
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cells using 5-Aza-dC could induce mRNA expression of
both OX40L and 41BBL on two different CRC cell lines
(Figure 1 & 2). Although a greater than 5-fold induction
of mRNA was detected in SW620 cells treated with 5-
Aza-dC, we did not observe a robust increase in protein
expression upon 5-Aza-dC treatment of these cells
(Figure 3). These discordant results could simply be a re-
sult of the time of evaluation post-treatment. 41BBL
mRNA was maximally increased 72 hr post-treatment
with 5-Aza-dC, while protein expression was evaluated
after 24 h of treatment to keep cell death low at time of
evaluation. Current studies are underway to determine if
5-Aza-dC can indeed upregulate protein expression at
later times post-treatment.
HDAC inhibition has been shown to be involved in
modulating the expression of TNF family members
[69,70]. In this study we extended analysis to other TNF
family members and found that both 41BBL and OX40L
expression could also be modulated by inhibition of
HDACs. We found that the expression of both OX40L
and 41BBL was increased on the surface of tumor cells
treated with TSA for 24 hr (Figure 3) or 48 hr (Figure 4).
Interestingly, the impact of HDAC inhibition by TSA on
41BBL protein expression was much more robust than
changes observed in the expression of OX40L protein
following TSA treatment. Studies are currently under-
way to evaluate changes in histone acetylation at the
OX40L promoter to determine how acetylation is im-
pacted by TSA inhibition of HDACs. We also observed
increased expression of co-stimulatory proteins as long
as four days after TSA-treatment and irradiation. While
many of the cellular stress response genes are acute re-
sponse genes whose expression is altered transiently,
other genes remain altered for prolonged periods of time
[71-73]. As such, altered gene expression following radi-
ation treatment that is sustained is not unexpected.
The TNF family includes numerous costimulatory
molecules known to play an important role in CD8+ T
cell activation and survival. We found that inhibition of
HDACs in tumor cells resulted in enhanced T-cell sur-
vival (Figure 6) and activation (Figure 7). To our know-
ledge this is the first study to explore the impact of
radiation-induced epigenetic changes in tumor cells on
the quality of anti-tumor CTLs. We are currently inves-
tigating if, by promoting T-cell survival and activation,
the altered expression of these specific genes by HDACi
enhances the tumor cells’ susceptibility to T-cell-medi-
ated immune attack in a manner similar to observations
in irradiated tumor cells (submitted manuscript). Future
studies seek to more fully investigate if increased signal-
ing through CD25 is directly responsible for the in-
creased survival of T-cells by evaluating T cells after
shorter periods of co-incubation as well as investing
intracellular regulators of T-cell apoptosis.
HDACs enzymes reverse the activity of HATs by re-
moving acetyl group and thus suppressing gene tran-
scription. In several tumors, the expression of HATs is
down-regulated, whereas HDACs is upregulated [74,75].
As previously mentioned, alteration of HAT and HDAC
activity has been observed in tumor cell lines. HDACi
induce a potent anticancer response by inhibiting
HDACs [76,77]. HDACi have various biological effects,
such as inhibition of cell cycle at G1/G2 phase, induc-
tion of differentiation and apoptosis of tumor cells
[78-80]. Our results reveal that radiation treatment
changes the epigenetic landscape of the 41BBL gene via
an increase in histone acetylation, displaying a marked
increase in H3 acetylation at this specific promoter, as
compared to our positive control of cells treated with
the HDACi, TSA. We also observed that TSA induced
robust 41BBL mRNA changes at earlier times of treat-
ment (8 h and 24 h) while radiation-induced changes
took longer and were greatest at later times of treatment
(48 h and 72 h). These data, in combination with
increase promoter acetylation, suggest that radiation me-
diated effects take longer to modulate histone acetyl-
ation events than direct modulators such as TSA. This
could be related to differences in modulation of HATs
versus HDAC inhibitors. Current lab efforts are pursuing
the mechanism for these epigenetic changes in primary
carcinoma cells; specifically, does IR treatment change
the activity of HATs, HDACs or both? If HDACs are
involved, specific HDAC inhibitors will be utilized to
identify which HDACs suppression(s) are vital for the
upregulation of 41BBL expression. Also, how long can
these epigenetic changes be maintained to promote
increased effector T-cell function? Finally, we note that
expression of OX40L and 41BBL varied with different
concentrations of drug exposure. Our focus here is to
describe a novel gene regulatory mechanism by epigen-
etic modification in response to irradiation. However,
the application of clinically relevant doses of TSA and
5-Aza-dC, which might be combined with radiation, will
also require a further investigation in a broad range of
tumor cells.
Conclusions
The current study was meant to enhance our ability to
design cancer immunotherapy (CIT) approaches in com-
bination with RT. A better understanding of how IR
modulates the expression of 41BBL and OX40L will
allow improvement in our ability to use RT to specific-
ally enhance CTL killing. Epigenetic mechanisms of gene
expression could be an alternative therapeutic approach
to enhancing these important T-cell signals. This
approach is particularly relevant given the toxicities as-
sociated with using agonistic antibodies to 41BB and
anti-OX40 antibodies in the clinic [28,81]. Alternate
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ways of triggering these signal pathways would be widely
applicable in current CIT approaches. Furthermore, if ra-
diation is shown to have a profound and consistent
effect on immune stimulatory gene expression, this
would provide support for using IR in conjunction with
CIT strategies to specifically enhance such signals to
T-cells arriving at tumor sites and optimize anti-tumor
CTL responses.
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